Citations (116)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Kelan L. Thomas, Robert Jesse, Nicky J. Mehtani, Jennifer M. Mitchell & Brian T. Anderson. (2024) Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics. Journal of Psychoactive Drugs 56:2, pages 206-210.
Read now
Read now
Andrew Troy Hodge, Suporn Sukpraprut-Braaten, Matthew Narlesky & Robert C. Strayhan. (2023) The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. Journal of Psychoactive Drugs 55:1, pages 40-50.
Read now
Read now
Jeremy Carlier, Sara Malaca, Marilyn A. Huestis, Adriano Tagliabracci, Anastasio Tini & Francesco P. Busardò. (2022) Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations. Expert Opinion on Drug Metabolism & Toxicology 18:12, pages 831-840.
Read now
Read now
Hartej Gill, Barjot Gill, David Chen-Li, Sabine El-Halabi, Nelson B. Rodrigues, Danielle S. Cha, Orly Lipsitz, Yena Lee, Joshua Daniel Rosenblat, Amna Majeed, Rodrigo B. Mansur, Flora Nasri, Roger Ho & Roger S. McIntyre. (2020) The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Review of Neurotherapeutics 20:12, pages 1263-1273.
Read now
Read now
Justin P. Reinert, Kayla Colunga, Alexandria Etuk, Victoria Richardson & Rebecca L. Dunn. (2020) Management of overdoses of salvia, kratom, and psilocybin mushrooms: a literature review. Expert Review of Clinical Pharmacology 13:8, pages 847-856.
Read now
Read now
Kodye L. Abbott, Patrick C. Flannery, Kristina S. Gill, Dawn M. Boothe, Muralikrishnan Dhanasekaran, Sridhar Mani & Satyanarayana R. Pondugula. (2020) Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metabolism Reviews 52:1, pages 44-65.
Read now
Read now
Rui Filipe Libânio Osório Marta. (2019) Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metabolism Reviews 51:3, pages 378-387.
Read now
Read now
Rafaela Costa, Nuno G. Oliveira & Ricardo Jorge Dinis-Oliveira. (2019) Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metabolism Reviews 51:3, pages 293-313.
Read now
Read now
Leandro Nóbrega & Ricardo Jorge Dinis-Oliveira. (2018) The synthetic cathinone α-pyrrolidinovalerophenone (α-PVP): pharmacokinetic and pharmacodynamic clinical and forensic aspects. Drug Metabolism Reviews 50:2, pages 125-139.
Read now
Read now
Articles from other publishers (107)
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh, James J. Rucker, Latha Velayudhan, David M. Taylor, Allan H. Young, Dag Aarsland, Anthony C. Vernon & Sandrine Thuret. (2024) Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & Therapeutics 258, pages 108641.
Crossref
Crossref
Nur Damla Korkmaz, Ugur Cikrikcili, Merve Akan & Emrah Yucesan. (2024) Psychedelic therapy in depression and substance use disorders. European Journal of Neuroscience.
Crossref
Crossref
Kimberly Sakai, Ellen R. Bradley, Joseph A. Zamaria, Gabrielle Agin-Liebes, D. Parker Kelley, Alexander Fish, Valeria Martini, Michelle C. Ferris, Emma Morton, Erin E. Michalak, Aoife O’Donovan & Joshua D. Woolley. (2024) Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology.
Crossref
Crossref
Jan Thomann, Karolina E. Kolaczynska, Oliver V. Stoeckmann, Deborah Rudin, Patrick Vizeli, Marius C. Hoener, Christopher R. Pryce, Franz X. Vollenweider, Matthias E. Liechti & Urs Duthaler. (2024) In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Frontiers in Pharmacology 15.
Crossref
Crossref
Tobias P. Whelan, Eileen Daly, Nicolaas A. Puts, Paula Smith, Carrie Allison, Simon Baron-Cohen, Ekaterina Malievskaia, Declan G. M. Murphy & Grainne M. McAlonan. (2024) The ‘PSILAUT’ protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin. BMC Psychiatry 24:1.
Crossref
Crossref
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles Saylor, George Danias, Lauren Lepow & Rachel Yehuda. (2024) The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Current Neuropharmacology 22:4, pages 636-735.
Crossref
Crossref
Antonin Rouaud, Abigail E. Calder & Gregor Hasler. (2024) Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. Journal of Psychopharmacology 38:3, pages 217-224.
Crossref
Crossref
Munchelou M. Gomonit, Britni Skillman & Madeleine J. Swortwood. (2023)
Quantification of psilocin in human whole blood using liquid chromatography–tandem mass spectrometry (
LC–MS
/
MS
)
. Journal of Forensic Sciences 69:2, pages 678-687.
Crossref
Crossref
Burton J. TabaacKenneth Shinozuka, Alejandro ArenasBryce D. BeutlerKirsten CherianViviana D. EvansChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin. American Journal of Therapeutics 31:2, pages e121-e132.
Crossref
Crossref
Salma Laabi, Claire LeMmon, Callie Vogel, Mariana Chacon & Victor M. JimenezJr.Jr.. (2024) Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights. International Immunopharmacology 130, pages 111753.
Crossref
Crossref
Tessa Watford & Naqash Masood. (2023) Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review. Clinical Psychopharmacology and Neuroscience 22:1, pages 2-12.
Crossref
Crossref
Curro Polo-Castellano, Rosa María Mateos, Francisco Visiedo, Miguel Palma, Gerardo Fernández Barbero & Marta Ferreiro-González. (2024) Optimization of the Enzymatic Extraction of Naringenin from Pink Grapefruit Pulp (Citrus × paradisi Macfad.). Agronomy 14:3, pages 402.
Crossref
Crossref
Sofia Audrey B. Gonzales, Christine Alexopoulos & Daniel G. Arkfeld. (2024) Potential Benefits of Psilocybin for Lupus Pain: A Case Report. Current Rheumatology Reviews 20:1, pages 97-99.
Crossref
Crossref
Felicia Reed & Claire J. Foldi. (2024) Do the therapeutic effects of psilocybin involve actions in the gut?. Trends in Pharmacological Sciences 45:2, pages 107-117.
Crossref
Crossref
Alberto Hernandez-Leon, Raúl Iván Escamilla-Orozco, Aylín R. Tabal-Robles, David Martínez-Vargas, Leticia Romero-Bautista, Gerson Escamilla-Soto, Osiris S. González-Romero, Martín Torres-Valencia & María Eva González-Trujano. (2024) Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice. Journal of Ethnopharmacology 320, pages 117415.
Crossref
Crossref
Luca Maurice Richter, Jozef Al-Gousous, Gabriel Lima Barros de Araujo, Neal M. Davies & Raimar Löbenberg. (2024) Assessing the utility of in silico tools in early drug development: The case of a pharmaceutically relevant formulation of the prodrug psilocybin. Journal of Drug Delivery Science and Technology 92, pages 105305.
Crossref
Crossref
Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet & Dean Calhoun. (2023) The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. Journal of Applied Toxicology 44:2, pages 216-234.
Crossref
Crossref
Sheetal A. Raithatha, Jillian M. Hagel, Kaveh Matinkhoo, Lisa Yu, David Press, Sarah G. Cook, Govinda Sharma, D. Dhananjaya, Glynnis Jensen, Jessica B. Lee, Charlie Cai, Jonathan Gallant, Jaideep Bains, Joseph E. Tucker & Peter J. Facchini. (2023) Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders. Journal of Medicinal Chemistry 67:2, pages 1024-1043.
Crossref
Crossref
Nathan T. Jones, Laura Wagner, Molly C. Pellitteri Hahn, Cameron O. Scarlett & Cody J. Wenthur. (2024) In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. Frontiers in Psychiatry 14.
Crossref
Crossref
Andreas Halman, Geraldine Kong, Jerome Sarris & Daniel Perkins. (2023) Drug–drug interactions involving classic psychedelics: A systematic review. Journal of Psychopharmacology 38:1, pages 3-18.
Crossref
Crossref
Cécile Adamski, Jules-Antoine Vaucel, Camille Paradis, Clément Brunet, Audrey Nardon, Arnaud Courtois, Florian Malard, Nadège Castaing & Magali Labadie. (2024) Intoxication familiale involontaire avec une tablette de chocolat contenant du Psilocybe cubensis : une étude de cas. Toxicologie Analytique et Clinique.
Crossref
Crossref
Timothy J. Wiegand. 2024. Encyclopedia of Toxicology. Encyclopedia of Toxicology
541
544
.
Adam Wojtas & Krystyna Gołembiowska. (2023) Molecular and Medical Aspects of Psychedelics. International Journal of Molecular Sciences 25:1, pages 241.
Crossref
Crossref
Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram, Ikram ul Haq, Benish Javed, Sadeed Sabir, Yasha Kazim & Sehrish Ashfaq. (2023) Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. Molecular Biotechnology.
Crossref
Crossref
Marilia Santoro Cardoso, Kelly Francisco da Cunha, Izabelly Geraldes Silva, Taís Regina Fiorentin, Eduardo G de Campos & Jose Luiz Costa. (2023) Development and validation of a sensitive LC–MS-MS method to quantify psilocin in authentic oral fluid samples. Journal of Analytical Toxicology 47:9, pages 835-841.
Crossref
Crossref
Marco Pepe, Mohsen Hesami, Karla A. de la Cerda, Melissa L. Perreault, Tom Hsiang & Andrew Maxwell Phineas Jones. (2023) A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond. Biotechnology Advances 69, pages 108247.
Crossref
Crossref
Francisco Madrid-Gambin, David Fabregat-Safont, Alex Gomez-Gomez, Eulàlia Olesti, Natasha L. Mason, Johannes G. Ramaekers & Oscar J. Pozo. (2023) Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. Biomedicine & Pharmacotherapy 169, pages 115775.
Crossref
Crossref
Adam Waldbillig, Maria Baranova, Sarah Neumann, Jonathan Andrade & Sharan Sidhu. (2023) Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds. Frontiers in Fungal Biology 4.
Crossref
Crossref
Andrew A. BolingerNoelle C. AnastasioKathryn A. CunninghamJia Zhou. 2023. 2023 Medicinal Chemistry Reviews. 2023 Medicinal Chemistry Reviews
53
81
.
María Marcela Velásquez Toledo. (2023) Evidencias y perspectivas del potencial antidepresivo del “alcaloide mágico” psilocibina: una revisión narrativa. Cultura y Droga 28:35, pages 91-113.
Crossref
Crossref
Arya Rahbarnia, Zhaoxia Li & Paul J. Fletcher. (2023) Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test. Psychopharmacology.
Crossref
Crossref
Xue Chen, Jing Li, Lisa Yu, Francesca Maule, Limei Chang, Jonathan A. Gallant, David J. Press, Sheetal A. Raithatha, Jillian M. Hagel & Peter J. Facchini. (2023) A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines. Journal of Biological Chemistry 299:10, pages 105231.
Crossref
Crossref
Pravesh Sharma, Quang Anh Nguyen, Sadie J Matthews, Erin Carpenter, Douglas B Mathews, Christi A Patten & Christopher J Hammond. (2023) Psilocybin history, action and reaction: A narrative clinical review. Journal of Psychopharmacology 37:9, pages 849-865.
Crossref
Crossref
Amir Garakani, Jeanne L. Alexander, Calvin R. Sumner, Janet H. Pine, Lawrence S. Gross, Charles L. Raison, Scott T. Aaronson & David A. Baron. (2023) Psychedelics, With a Focus on Psilocybin: Issues for the Clinician. Journal of Psychiatric Practice 29:5, pages 345-353.
Crossref
Crossref
Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff, Nikolaj Speth, Tobias G. Brandt, Julia Czurylo, Mengfei Xiong, Naja S. Jessen, Agata Casado-Sainz, Vladimir Shalgunov, Celia Kjaerby, Grzegorz Satała, Andrzej J. Bojarski, Anders A. Jensen, Matthias M. Herth, Paul Cumming, Agnete Overgaard & Mikael Palner. (2023) Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. Molecular Psychiatry 28:9, pages 3829-3841.
Crossref
Crossref
A.M. Costa, M. Silva-Carvalho, A. Madureira-Carvalho, R.J. Dinis-Oliveira & D. Dias-da-Silva. (2023) P05-02: Assessment of the CYP450 inhibitory activity of psilocybin, psilocin, LSD, 5-MeO-DMT and mescaline: An in vitro study. Toxicology Letters 384, pages S100.
Crossref
Crossref
Scott G. Harroun & Alexis Vallée‐Bélisle. (2023) Methods to Characterise Enzyme Kinetics with Biological and Medicinal Substrates: The Case of Alkaline Phosphatase. Chemistry–Methods 3:8.
Crossref
Crossref
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, Albert Garcia-Romeu & Mauricio A Garcia-Barrera. (2023) Psilocybin’s effects on cognition and creativity: A scoping review. Journal of Psychopharmacology 37:7, pages 635-648.
Crossref
Crossref
Lilith Becher, Federico Nanni & Michael Koslowski. (2023) Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen. Nervenheilkunde 42:07/08, pages 450-458.
Crossref
Crossref
Matthew Meyer & Jason Slot. (2023) The evolution and ecology of psilocybin in nature. Fungal Genetics and Biology 167, pages 103812.
Crossref
Crossref
Eliza Milliken, Peter Galettis & Jenny Martin. (2023) A review of psilocybin: chemistry, clinical uses and future research directions. Australian Journal of Chemistry 76:5, pages 258-263.
Crossref
Crossref
D. P. Effinger, S. G. Quadir, M. C. Ramage, M. G. Cone & M. A. Herman. (2023) Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Translational Psychiatry 13:1.
Crossref
Crossref
John R. Kelly, Gerard Clarke, Andrew Harkin, Sinead C. Corr, Stephen Galvin, Vishnu Pradeep, John F. Cryan, Veronica O'Keane & Timothy G. Dinan. (2023) Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. International Journal of Clinical and Health Psychology 23:2, pages 100349.
Crossref
Crossref
Timur Zanikov, Marta Gerasymchuk, Esmaeel Ghasemi Gojani, Gregory Ian Robinson, Shima Asghari, Alyssa Groves, Lucie Haselhorst, Sanjana Nandakumar, Cora Stahl, Mackenzie Cameron, Dongping Li, Rocio Rodriguez-Juarez, Alexandra Snelling, Darryl Hudson, Anna Fiselier, Olga Kovalchuk & Igor Kovalchuk. (2023) The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice. Molecules 28:6, pages 2624.
Crossref
Crossref
Jing Wang, Min Liang, Qing Shang, Hongyan Qian, Ran An, Hua Liu, Gaojie Shao, Tao Li & Xinshe Liu. (2023)
Psilocin suppresses methamphetamine‐induced hyperlocomotion and acquisition of conditioned place preference via
D2R
‐mediated
ERK
signaling
. CNS Neuroscience & Therapeutics 29:3, pages 831-841.
Crossref
Crossref
Megan Pedicini & Zachary A. Cordner. (2023) Utility of preclinical models in the study of psilocybin – A comprehensive review. Neuroscience & Biobehavioral Reviews 146, pages 105046.
Crossref
Crossref
Curro Polo-Castellano, Rosa María Mateos, Francisco Visiedo, Miguel Palma, Gerardo F. Barbero & Marta Ferreiro-González. (2023) Optimizing an Enzymatic Extraction Method for the Flavonoids in Moringa (Moringa oleifera Lam.) Leaves Based on Experimental Designs Methodologies. Antioxidants 12:2, pages 369.
Crossref
Crossref
Hang Wang & Ying Wang. (2022) Matrix-assisted laser-desorption/ionization–mass spectrometric imaging of psilocybin and its analogues in psychedelic mushrooms using a cesium chloride-coated target plate. Analytical and Bioanalytical Chemistry 415:4, pages 735-745.
Crossref
Crossref
Sara Malaca, Charline Bottinelli, Laurent Fanton, Nathalie Cartiser, Jeremy Carlier & Francesco Paolo Busardò. (2023) α-Methyltryptamine (α-MT) Metabolite Profiling in Human Hepatocyte Incubations and Postmortem Urine and Blood. Metabolites 13:1, pages 92.
Crossref
Crossref
Juliet Meccia, Joëlle Lopez & Rosemary C. Bagot. (2022) Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. Psychopharmacology 240:1, pages 27-40.
Crossref
Crossref
Susanna M. Badalyan, Sylvie Morel, Anush Barkhudaryan & Sylvie Rapior. 2023. Mushrooms with Therapeutic Potentials. Mushrooms with Therapeutic Potentials
1
54
.
Raphaël Serreau, Ammar Amirouche, Amine Benyamina & Sabine Berteina-Raboin. (2022) A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe. Pharmaceuticals 16:1, pages 40.
Crossref
Crossref
Caroline A. MacCallum, Lindsay A. Lo, Carly A. Pistawka & Jagpaul Kaur Deol. (2022) Therapeutic use of psilocybin: Practical considerations for dosing and administration. Frontiers in Psychiatry 13.
Crossref
Crossref
Dominique Strauss, Soumya Ghosh, Zurika Murray & Marieka Gryzenhout. (2022) Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. 3 Biotech 12:12.
Crossref
Crossref
Ricardo Irizarry, Amelia Winczura, Omar Dimassi, Navpreet Dhillon, Annu Minhas & Jeanpaul Larice. (2022) Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis. Cureus.
Crossref
Crossref
Estella Tembe Fokunang, Mbong Grace Annih, Lem Edith Abongwa, Manju Evelyn Bih, Tchadji Mayoudom Vanessa, Dobgima John Fomnboh & Charles Fokunang. 2022. Current Topics in Functional Food. Current Topics in Functional Food.
Dev B Goel & Sarju Zilate. (2022) Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus.
Crossref
Crossref
Poonam Bhadoria & Venkatnarayan Ramanathan. (2022) Conformational Landscape and Properties of Psilocybin: A Computational Approach. ChemistrySelect 7:37.
Crossref
Crossref
Devon Stoliker, Gary F. Egan, Karl J. Friston & Adeel Razi. (2022) Neural Mechanisms and Psychology of Psychedelic Ego Dissolution. Pharmacological Reviews 74:4, pages 876-917.
Crossref
Crossref
Aparup Patra & Ashis K. Mukherjee. (2022) Mushroom mycetism – A neglected and challenging medical emergency in the Indian subcontinent: A road map for its prevention and treatment. Toxicon 217, pages 56-77.
Crossref
Crossref
D. Dias da Silva, A.M. Brito-da-Costa, S. Lemos Martins, R.J. Dinis-Oliveira & A. Madureira-Carvalho. (2022) P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applications. Toxicology Letters 368, pages S97.
Crossref
Crossref
Jesús G. Zorrilla & Antonio Evidente. (2022) Structures and Biological Activities of Alkaloids Produced by Mushrooms, a Fungal Subgroup. Biomolecules 12:8, pages 1025.
Crossref
Crossref
Seetal Dodd, Trevor R. Norman, Harris A. Eyre, Stephen M. Stahl, Arnie Phillips, André F. Carvalho & Michael Berk. (2022) Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectrums, pages 1-11.
Crossref
Crossref
Dina Fradkin. (2021) Psilocybin: A brief overview for psychiatric mental health nurse practitioners. Perspectives in Psychiatric Care 58:3, pages 1200-1203.
Crossref
Crossref
Wenya Zhai, Le Li, Junbo Zhao, Ping Xiang, Mengxi Liu, Yan Shi & Yonghui Dang. (2022)
Tentative identification of in vitro metabolites of
O
‐acetylpsilocin (psilacetin, 4‐AcO‐DMT) by UHPLC‐Q‐Orbitrap MS
. Drug Testing and Analysis 14:7, pages 1300-1309.
Crossref
Crossref
Nataliya Vorobyeva & Alena A. Kozlova. (2022) Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. Frontiers in Pharmacology 13.
Crossref
Crossref
Curro Polo-Castellano, José Á. Álvarez, Miguel Palma, Gerardo F. Barbero, Jesús Ayuso & Marta Ferreiro-González. (2022) Optimization through a Box–Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis). Journal of Fungi 8:6, pages 598.
Crossref
Crossref
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm & Christopher S. Stauffer. (2022) Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 239:6, pages 1945-1976.
Crossref
Crossref
Robert Sotille, Herpreet Singh, Anne Weisman & Thomas Vida. (2022) Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus.
Crossref
Crossref
Franco Della-Felice, Aloisio de Andrade Bartolomeu & Ronaldo Aloise Pilli. (2022) The phosphate ester group in secondary metabolites. Natural Product Reports 39:5, pages 1066-1107.
Crossref
Crossref
Joyce Huang, Michelle Pham, William J. Panenka, William G. Honer & Alasdair M. Barr. (2022) Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity. Frontiers in Psychiatry 13.
Crossref
Crossref
Lin Zhou, Li-Li Guo, Masahiko Isaka, Zheng-Hui Li & He-Ping Chen. (2022) [20(22)E]-Lanostane Triterpenes from the Fungus Ganoderma australe. Journal of Fungi 8:5, pages 503.
Crossref
Crossref
Ricardo Jorge Dinis-Oliveira. (2022) The Genesis of a New Open-Access Journal Focused on the Latest Scientific Advances in Psychoactive Substances. Psychoactives 1:1, pages 1-6.
Crossref
Crossref
Elaine Meade, Sarah Hehir, Neil Rowan & Mary Garvey. (2022) Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. Journal of Fungi 8:3, pages 290.
Crossref
Crossref
Igor Elman, Amanda Pustilnik & David Borsook. (2022) Beating pain with psychedelics: Matter over mind?. Neuroscience & Biobehavioral Reviews 134, pages 104482.
Crossref
Crossref
Maurizio Coppola, Francesco Bevione & Raffaella Mondola. (2022) Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?. Journal of Xenobiotics 12:1, pages 41-52.
Crossref
Crossref
Benjamin Breen. (2021) The Failed Globalization of Psychedelic Drugs in the Early Modern World. The Historical Journal 65:1, pages 12-29.
Crossref
Crossref
Susan Ling, Felicia Ceban, Leanna M. W. Lui, Yena Lee, Kayla M. Teopiz, Nelson B. Rodrigues, Orly Lipsitz, Hartej Gill, Mehala Subramaniapillai, Rodrigo B. Mansur, Kangguang Lin, Roger Ho, Joshua D. Rosenblat, David Castle & Roger S. McIntyre. (2021) Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS Drugs 36:1, pages 17-30.
Crossref
Crossref
Andreia Machado Brito-da-Costa, Diana Dias da Silva, Áurea Madureira-Carvalho & Ricardo Jorge Dinis-Oliveira. 2022. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
2427
2455
.
Andreia Machado Brito-da-Costa, Diana Dias-da-Silva, Áurea Madureira-Carvalho & Ricardo Jorge Dinis-Oliveira. 2021. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
1
29
.
Sylvana Vilca-Melendez, Malin V. Uthaug & Julian L. Griffin. (2021) 1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?. Frontiers in Psychiatry 12.
Crossref
Crossref
A. Andreiev, E. Bucuci, J. Chue, C. Els & P. Chue. (2021) P.0623 The clinical relevance of the pharmacokinetics of psilocybin. European Neuropsychopharmacology 53, pages S458.
Crossref
Crossref
Robertas Strumila, Bénédicte Nobile, Laura Korsakova, Aiste Lengvenyte, Emilie Olie, Jorge Lopez-Castroman, Sébastien Guillaume & Philippe Courtet. (2021) Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. Pharmaceuticals 14:12, pages 1213.
Crossref
Crossref
Jiri Patocka, Ran Wu, Eugenie Nepovimova, Martin Valis, Wenda Wu & Kamil Kuca. (2021) Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms. International Journal of Molecular Sciences 22:4, pages 2218.
Crossref
Crossref
Andreia Machado Brito-da-Costa, Diana Dias-da-Silva, Nelson G. M. Gomes, Ricardo Jorge Dinis-Oliveira & Áurea Madureira-Carvalho. (2021) Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects. Pharmaceuticals 14:2, pages 116.
Crossref
Crossref
Klára Gotvaldová, Kateřina Hájková, Jan Borovička, Radek Jurok, Petra Cihlářová & Martin Kuchař. (2020)
Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom
Psilocybe cubensis
. Drug Testing and Analysis 13:2, pages 439-446.
Crossref
Crossref
Collin M. ReiffElon E. RichmanCharles B. NemeroffLinda L. CarpenterAlik S. WidgeCarolyn I. RodriguezNed H. KalinWilliam M. McDonald. (2021) Psychedelics and Psychedelic-Assisted Psychotherapy. FOCUS 19:1, pages 95-115.
Crossref
Crossref
Elyes Dahmane, Paul R. Hutson & Jogarao V. S. Gobburu. (2020) Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Psilocybin/Psilocin. Clinical Pharmacology in Drug Development 10:1, pages 78-85.
Crossref
Crossref
Caitlin Thompson & Attila Szabo. (2020) Psychedelics as a novel approach to treating autoimmune conditions. Immunology Letters 228, pages 45-54.
Crossref
Crossref
Andreia Machado Brito-da-Costa, Diana Dias-da-Silva, Nelson G. M. Gomes, Ricardo Jorge Dinis-Oliveira & Áurea Madureira-Carvalho. (2020) Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact. Pharmaceuticals 13:11, pages 334.
Crossref
Crossref
Izumi Morita, Hiroyuki Oyama, Yuki Kiguchi, Akari Oguri, Natsumi Fujimoto, Atsuko Takeuchi, Rie Tanaka, Jun Ogata, Ruri Kikura-Hanajiri & Norihiro Kobayashi. (2020) Immunochemical monitoring of psilocybin and psilocin to identify hallucinogenic mushrooms. Journal of Pharmaceutical and Biomedical Analysis 190, pages 113485.
Crossref
Crossref
Carl A Roberts, Isaac Osborne-Miller, Jon Cole, Suzanne H Gage & Paul Christiansen. (2020) Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use. Journal of Psychopharmacology 34:9, pages 999-1007.
Crossref
Crossref
Andrew R. Chadeayne, Duyen N. K. Pham, Brian G. Reid, James A. Golen & David R. Manke. (2020)
Active Metabolite of Aeruginascin (4-Hydroxy-
N
,
N
,
N
-trimethyltryptamine): Synthesis, Structure, and Serotonergic Binding Affinity
. ACS Omega 5:27, pages 16940-16943.
Crossref
Crossref
N. Milne, P. Thomsen, N. Knudsen, P. Rubaszka, M. Kristensen & I. Borodina. (2020) Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives. Metabolic Engineering 60, pages 25-36.
Crossref
Crossref
Collin M. ReiffElon E. RichmanCharles B. NemeroffLinda L. CarpenterAlik S. WidgeCarolyn I. RodriguezNed H. KalinWilliam M. McDonald. (2020) Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry 177:5, pages 391-410.
Crossref
Crossref
Ricardo Jorge Dinis-Oliveira & Teresa Magalhães. (2020) Abuse of Licit and Illicit Psychoactive Substances in the Workplace: Medical, Toxicological, and Forensic Aspects. Journal of Clinical Medicine 9:3, pages 770.
Crossref
Crossref
Alexander M. Sherwood, Poncho Meisenheimer, Gary Tarpley & Robert B. Kargbo. (2020) An Improved, Practical, and Scalable Five-Step Synthesis of Psilocybin. Synthesis 52:05, pages 688-694.
Crossref
Crossref
Alexander M. Sherwood, Adam L. Halberstadt, Adam K. Klein, John D. McCorvy, Kristi W. Kaylo, Robert B. Kargbo & Poncho Meisenheimer. (2020) Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin. Journal of Natural Products 83:2, pages 461-467.
Crossref
Crossref
Nicole S. Jones & Jeffrey H. Comparin. (2020) Interpol review of controlled substances 2016–2019. Forensic Science International: Synergy 2, pages 608-669.
Crossref
Crossref
Uttam Garg, Jeff Knoblauch, C. Clinton FrazeeIIIIII, Adrian Baron & Mary Dudley. 2020. Toxicology Cases for the Clinical and Forensic Laboratory. Toxicology Cases for the Clinical and Forensic Laboratory
379
382
.
Andrew R. Chadeayne, Duyen N. K. Pham, James A. Golen & David R. Manke. (2019)
The fumarate salts of the
N
-isopropyl-
N
-methyl derivatives of DMT and psilocin
. Acta Crystallographica Section E Crystallographic Communications 75:9, pages 1316-1320.
Crossref
Crossref
Ricardo Jorge Dinis-Oliveira, Carolina Lança Pereira & Diana Dias da Silva. (2019) Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12:3, pages 184-194.
Crossref
Crossref
Emma Honyiglo, Angélique Franchi, Nathalie Cartiser, Charline Bottinelli, Anne‐Sophie Advenier, Fabien Bévalot & Laurent Fanton. (2018) Unpredictable Behavior Under the Influence of “Magic Mushrooms”: A Case Report and Review of the Literature. Journal of Forensic Sciences 64:4, pages 1266-1270.
Crossref
Crossref
Amitava Dasgupta. 2019. Critical Issues in Alcohol and Drugs of Abuse Testing. Critical Issues in Alcohol and Drugs of Abuse Testing
477
494
.
Kenichi Tamama & Michael J. Lynch. 2020. Substance Use Disorders. Substance Use Disorders
463
502
.
Haden A. Geiger, Madeline G. Wurst & R. Nathan Daniels. (2018) DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience 9:10, pages 2438-2447.
Crossref
Crossref
Pia Simona Bruni, Katharina Elisabeth Grafinger, Susanne Nussbaumer, Stefan König, Stefan Schürch & Wolfgang Weinmann. (2018) Study of the in vitro and in vivo metabolism of 4-HO-MET. Forensic Science International 290, pages 103-110.
Crossref
Crossref